Meeting of the National Vaccine Advisory Committee, 40775-40776 [2018-17618]

Download as PDF Federal Register / Vol. 83, No. 159 / Thursday, August 16, 2018 / Notices ACTION: Notice. As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a meeting. The meeting will be open to the public. DATES: The meeting will take place on Thursday, September 13, 2018, from 8:00 a.m.–5:00 p.m. ET. ADDRESSES: Crystal City Marriott at Reagan National Airport, 1999 Jefferson Davis Highway, Arlington, VA 22202. FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Mary E. Switzer Building, 330 C Street SW, Suite L100, Washington, DC 20024. Phone: (202) 795–7697; Fax: (202) 691–2102; Email: ACBTSA@ hhs.gov. SUMMARY: The ACBTSA provides advice to the Secretary through the Assistant Secretary for Health. The Committee advises on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national biovigilance data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met regularly since its establishment in 1997. The Committee will meet on September 13, 2018 to receive presentations on material pertinent to exploring the topic of ‘‘Defining a tolerable risk for infectious diseases from a patient’s perspective.’’ Historical aspects of combating infectious disease risks in the blood supply, ongoing national and global efforts towards mitigating those risks, and emerging considerations shall be presented to the Committee. The full Committee will receive an interim report from the ACBTSA Blood Sustainability subcommittee and additional topics that are pertinent to sradovich on DSK3GMQ082PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:15 Aug 15, 2018 Jkt 244001 the mission of the Committee may be added to the agenda. The public will have an opportunity to present their views to the Committee during public comment session scheduled for the meeting. Comments will be limited to five minutes per speaker and must be pertinent to the discussion. Pre-registration is required for participation in the public comment session. Any member of the public who would like to participate in this session is required to submit their name, email, and comment summary prior to close of business on September 7, 2018. If it is not possible to provide 30 copies of the material to be distributed at the meeting, then individuals are requested to provide a minimum of one (1) copy of the document(s) to be distributed prior to the close of business on September 7, 2018. It is also requested that any member of the public who wishes to provide comments to the Committee utilizing electronic data projection submit the necessary material to the Designated Federal Officer prior to the close of business on September 7, 2018. Dated: August 9, 2018. James J. Berger, Senior Advisor for Blood and Tissue Policy. [FR Doc. 2018–17617 Filed 8–15–18; 8:45 am] BILLING CODE 4150–41–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that a meeting is scheduled to be held for the National Vaccine Advisory Committee (NVAC). The meeting will be open to the public; public comment sessions will be held during the meeting. DATES: The meeting will be held on September 12 and 13, 2018. The meeting times and agenda will be posted on the NVAC website at https:// www.hhs.gov/nvpo/nvac/meetings/ index.html as soon as they become available. SUMMARY: U.S. Department of Health and Human Services, Hubert H. Humphrey Building, Room 800, 200 Independence Avenue SW, Washington, ADDRESSES: PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 40775 DC 20201. The meeting can also be accessed through a live webcast on both days of the meeting. For more information, visit https://www.hhs.gov/ nvpo/nvac/meetings/. Pre-registration is required for members of the public who wish to attend the meeting and who wish to participate in a public comment session. Individuals who wish to attend the meeting and/or participate in a public comment session should register at https://www.hhs.gov/nvpo/nvac/ meetings/. Participants may also register by emailing nvpo@hhs.gov or by calling (202) 690–5566 and providing their name, organization, and email address. FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal Officer, National Vaccine Program Office, U.S. Department of Health and Human Services, Room 715H, Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Phone: (202) 690–5566; email: nvac@ hhs.gov. SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. During the September 2018 NVAC meeting, sessions will consist of presentations on valuing vaccines, including presentations on the role of vaccines in combatting antibiotic resistance; vaccine innovation, including presentations on financing, new technologies, and development of new vaccines; lessons from the field, with focus on Ebola and the new Shingles vaccine; and a session on HPV vaccination for cancer prevention. Please note that agenda items will be related to the charge of the Committee and are subject to change as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: https:// www.hhs.gov/nvpo/nvac/. Public attendance at the meeting is limited to the available space. Individuals who plan to attend in person and need special assistance, such as sign language interpretation or other reasonable accommodations, E:\FR\FM\16AUN1.SGM 16AUN1 40776 Federal Register / Vol. 83, No. 159 / Thursday, August 16, 2018 / Notices should notify the National Vaccine Program Office at the address/phone number listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at https://www.hhs.gov/ nvpo/nvac/meetings/. Members of the public will have the opportunity to provide comments at the NVAC meeting during the public comment periods designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit their written comments. Written comments should not exceed three pages in length. Individuals submitting written comments should email their comments to the National Vaccine Program Office (nvpo@hhs.gov) at least five business days prior to the meeting. Dated: July 31, 2018. Roula K. Sweis, Chief of Management and Operations, National Vaccine Program Office. [FR Doc. 2018–17618 Filed 8–15–18; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant (R34). Date: September 10, 2018. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). VerDate Sep<11>2014 17:15 Aug 15, 2018 Jkt 244001 Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G41B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC9823, Bethesda, MD 20892–9823, (240) 669–5068, zhuqing.li@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 10, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–17676 Filed 8–15–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental and Craniofacial Research; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: September 13, 2018. Open: 8:30 a.m. to 12:30 p.m. Agenda: Report to the Director, NIDCR. Place: National Institutes of Health Building 35, Room 620/630, 35 Convent Drive, Bethesda, MD 20892. Closed: 1:30 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, Building 35, Room 620/630, 35 Convent Drive, Bethesda, MD 20892. PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Contact Person: Alicia J. Dombroski, Ph.D., Director, Division of Extramural Activities, National Institute of Dental & Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, 301–594–4805, adombroski@nidcr.nih.gov. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: August 10, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–17679 Filed 8–15–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Analytical Services Center for Medications Development (8938). Date: September 25, 2018. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Lyle Furr, Scientific Review Officer, Office of Extramural Affairs, E:\FR\FM\16AUN1.SGM 16AUN1

Agencies

[Federal Register Volume 83, Number 159 (Thursday, August 16, 2018)]
[Notices]
[Pages 40775-40776]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-17618]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: National Vaccine Program Office, Office of the Assistant 
Secretary for Health, Office of the Secretary, Department of Health and 
Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services is hereby giving notice that a 
meeting is scheduled to be held for the National Vaccine Advisory 
Committee (NVAC). The meeting will be open to the public; public 
comment sessions will be held during the meeting.

DATES: The meeting will be held on September 12 and 13, 2018. The 
meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become 
available.

ADDRESSES: U.S. Department of Health and Human Services, Hubert H. 
Humphrey Building, Room 800, 200 Independence Avenue SW, Washington, DC 
20201. The meeting can also be accessed through a live webcast on both 
days of the meeting. For more information, visit https://www.hhs.gov/nvpo/nvac/meetings/.
    Pre-registration is required for members of the public who wish to 
attend the meeting and who wish to participate in a public comment 
session. Individuals who wish to attend the meeting and/or participate 
in a public comment session should register at https://www.hhs.gov/nvpo/nvac/meetings/. Participants may also register by emailing 
[email protected] or by calling (202) 690-5566 and providing their name, 
organization, and email address.

FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal 
Officer, National Vaccine Program Office, U.S. Department of Health and 
Human Services, Room 715H, Hubert H. Humphrey Building, 200 
Independence Avenue SW, Washington, DC 20201. Phone: (202) 690-5566; 
email: [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve optimal prevention against adverse 
reactions to vaccines. The NVAC was established to provide advice and 
make recommendations to the Director of the National Vaccine Program on 
matters related to the Program's responsibilities. The Assistant 
Secretary for Health serves as Director of the National Vaccine 
Program. During the September 2018 NVAC meeting, sessions will consist 
of presentations on valuing vaccines, including presentations on the 
role of vaccines in combatting antibiotic resistance; vaccine 
innovation, including presentations on financing, new technologies, and 
development of new vaccines; lessons from the field, with focus on 
Ebola and the new Shingles vaccine; and a session on HPV vaccination 
for cancer prevention. Please note that agenda items will be related to 
the charge of the Committee and are subject to change as priorities 
dictate. Information on the final meeting agenda will be posted prior 
to the meeting on the NVAC website: https://www.hhs.gov/nvpo/nvac/.
    Public attendance at the meeting is limited to the available space. 
Individuals who plan to attend in person and need special assistance, 
such as sign language interpretation or other reasonable 
accommodations,

[[Page 40776]]

should notify the National Vaccine Program Office at the address/phone 
number listed above at least one week prior to the meeting. For those 
unable to attend in person, a live webcast will be available. More 
information on registration and accessing the webcast can be found at 
https://www.hhs.gov/nvpo/nvac/meetings/.
    Members of the public will have the opportunity to provide comments 
at the NVAC meeting during the public comment periods designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit their written 
comments. Written comments should not exceed three pages in length. 
Individuals submitting written comments should email their comments to 
the National Vaccine Program Office ([email protected]) at least five 
business days prior to the meeting.

    Dated: July 31, 2018.
Roula K. Sweis,
Chief of Management and Operations, National Vaccine Program Office.
[FR Doc. 2018-17618 Filed 8-15-18; 8:45 am]
 BILLING CODE 4150-44-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.